| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,750,000 |
| Market
Cap: |
178.37(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.77 - $20.32 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 12.5 |
| Insider 6 Months : 13.1 |
| Insider 3/6 Months : 26 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Co.'s product candidates include GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers; and granulocyte macrophage colony-stimulating factor immunoadjuvant, which is to improve monocyte and neutrophil cytotoxicity against melanoma tumor cells and to improve activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
68,600 |
77,100 |
96,450 |
225,574 |
| Total Buy Value |
$872,910 |
$955,633 |
$1,130,787 |
$2,406,697 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
8 |
10 |
23 |
59 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Snehal |
CEO and CFO |
• • • |
2024-04-01 |
4 |
B |
$19.08 |
$57,240 |
D/D |
3,000 |
5,350,777 |
3.23 |
-26% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-03-22 |
4 |
B |
$19.98 |
$49,950 |
D/D |
2,500 |
5,347,777 |
3.23 |
-29% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-03-20 |
4 |
B |
$17.68 |
$26,520 |
D/D |
1,500 |
5,345,277 |
3.23 |
-24% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-03-05 |
4/A |
B |
$12.49 |
$43,715 |
D/D |
3,500 |
5,343,777 |
3.23 |
- |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-03-05 |
4 |
B |
$12.49 |
$380,945 |
D/D |
30,500 |
5,343,777 |
3.23 |
11% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-03-04 |
4 |
B |
$13.03 |
$53,423 |
D/D |
4,100 |
5,340,277 |
3.23 |
8% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-02-16 |
4 |
B |
$11.16 |
$120,528 |
D/D |
10,800 |
5,336,177 |
3.23 |
25% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2024-02-15 |
4 |
B |
$11.07 |
$140,589 |
D/D |
12,700 |
5,325,377 |
3.23 |
21% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-11-10 |
4 |
B |
$10.17 |
$50,838 |
D/D |
5,000 |
5,312,677 |
3.23 |
93% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-11-03 |
4 |
B |
$9.11 |
$31,885 |
D/D |
3,500 |
5,307,677 |
3.23 |
93% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-10-27 |
4 |
B |
$8.57 |
$4,285 |
D/D |
500 |
260,348 |
2.66 |
80% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-10-26 |
4 |
B |
$7.97 |
$19,925 |
D/D |
2,500 |
5,304,177 |
3.15 |
99% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-10-25 |
4 |
B |
$7.91 |
$19,775 |
D/D |
2,500 |
5,301,677 |
3.15 |
73% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-10-10 |
4 |
B |
$9.07 |
$9,070 |
D/D |
1,000 |
5,299,177 |
3.15 |
39% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-10-04 |
4 |
B |
$8.63 |
$17,260 |
D/D |
2,000 |
5,298,177 |
3.15 |
-2% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-09-26 |
4 |
B |
$8.71 |
$5,226 |
D/D |
600 |
259,848 |
2.74 |
4% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-09-19 |
4 |
B |
$8.95 |
$35,800 |
D/D |
4,000 |
5,296,177 |
3.23 |
3% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-09-11 |
4 |
B |
$9.48 |
$9,480 |
D/D |
1,000 |
5,292,177 |
3.15 |
-4% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-08-22 |
4 |
B |
$9.97 |
$9,970 |
D/D |
1,000 |
5,291,177 |
3.15 |
5% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-08-04 |
4 |
B |
$10.55 |
$21,100 |
D/D |
2,000 |
5,290,177 |
3.15 |
5% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-07-21 |
4 |
B |
$9.20 |
$9,200 |
D/D |
1,000 |
5,288,177 |
3.15 |
26% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-07-13 |
4 |
B |
$9.49 |
$2,373 |
D/D |
250 |
259,248 |
2.66 |
13% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-05-17 |
4 |
B |
$11.69 |
$11,690 |
D/D |
1,000 |
5,287,177 |
3.15 |
-27% |
|
| Thompson Jaye |
VP Clinical Reg Affairs |
• – – |
2023-04-28 |
4 |
B |
$11.22 |
$2,805 |
D/D |
250 |
258,998 |
2.66 |
-17% |
|
| Patel Snehal |
CEO and CFO |
• • • |
2023-04-19 |
4 |
B |
$11.10 |
$77,700 |
D/D |
7,000 |
5,286,177 |
3.23 |
-17% |
|
106 Records found
|
|
Page 1 of 5 |
|
|
0.01 (0.07%) 
